Covered recipient · General Payments record
LAURA E SMITH
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant Medical
General Payments · PY2021–2024
$1,316.42
- Reported across 66 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $376.68 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $121.78 | 6 |
| Regeneron Healthcare Solutions, Inc. | $57.70 | 2 |
| GENZYME CORPORATION | $45.09 | 2 |
| Janssen Biotech, Inc. | $37.37 | 2 |
| Amgen Inc. | $28.26 | 1 |
| Organon LLC | $28.06 | 1 |
| Incyte Corporation | $23.06 | 1 |
| Tempus AI, Inc | $20.61 | 1 |
| Galderma Laboratories, L.P. | $14.75 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $24.65 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108220403 | CMS |
| ABBVIE INC. | $13.23 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108220405 | CMS |
| ABBVIE INC. | $13.89 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108220407 | CMS |
| ABBVIE INC. | $22.62 | 07/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108220409 | CMS |
| ABBVIE INC. | $34.02 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108220411 | CMS |
| ABBVIE INC. | $13.37 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108220413 | CMS |
| Amgen Inc. | $28.26 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117687920 | CMS |
| Galderma Laboratories, L.P. | $14.75 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145393136 | CMS |
| GENZYME CORPORATION | $29.23 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139844097 | CMS |
| GENZYME CORPORATION | $15.86 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139844111 | CMS |
| Incyte Corporation | $23.06 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141194835 | CMS |
| Janssen Biotech, Inc. | $16.01 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078328339 | CMS |
| Janssen Biotech, Inc. | $21.36 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078328327 | CMS |
| Organon Llc | $28.06 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136311107 | CMS |
| Regeneron Healthcare Solutions, Inc. | $19.41 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114374652 | CMS |
| Regeneron Healthcare Solutions, Inc. | $38.29 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114374654 | CMS |
| Tempus AI, Inc | $20.61 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150187304 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.